about us Cyndea Pharma independent

Similar documents
WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SERBIA

WCPT COUNTRY PROFILE December 2017 SWEDEN

Q1 What age are you?

Global EHS Resource Center

THE CARE WE PROMISE FACTS AND FIGURES 2017

Terms and Conditions. VISA Global Customer Assistance Services

Alcohol-related harm in Europe and the WHO policy response

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

Engagement in language assessment / Regions of Europe

Where we stand in EFORT

ESPEN Congress Geneva 2014 FOOD: THE FACTOR RESHAPING THE SIZE OF THE PLANET

LEBANON. WCPT COUNTRY PROFILE December 2018

Tobacco: World Markets and Trade

DENMARK. WCPT COUNTRY PROFILE December 2018

The cancer burden in the European Union and the European Region: the current situation and a way forward

European Status report on Alcohol and Health

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

Smokefree Policies in Europe: Are we there yet?

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

GERMANY. WCPT COUNTRY PROFILE December 2018

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017

67 Years of Leadership in Pharmacy. A Journey of Continuous Improvement

Drug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

Cross Border Genetic Testing for Rare Diseases

Main developments in past 24 hours

EUDY JUNIOR CAMP 2018 FIRST ANNOUNCEMENT

Highlighting in the WHO European Region:

Overall survival: 1 st line therapy

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

EURO POLIO PAGE Data as of 04 October 2005 (Week 38)

European status report on alcohol and health Leadership, awareness and commitment

World Connections Committee (WCC) Report

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

Best practices in collecting and processing data in CRC screening and after it

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

The EHRA White Book 2009 The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

Access to treatment and disease burden

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

Bio-Rad Laboratories. Hemoglobin Testing. VARIANT II Hemoglobin Testing System For HbA 1c

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Noncommunicable diseases progress monitoring. Are we meeting the time-bound United Nations targets?

Highlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance

Percutaneous Mitral Valve Therapies

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

European Community Pharmacy: a reference in Public Health

Overview of drug-induced deaths in Europe - What does the data tell us?

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

GLP in the European Union Ecolabel detergents, GLP and accreditation

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ

Table 6.1 Summary information for colorectal cancer in Ireland,

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers NZ & Australia

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

11 Melanoma of the skin

Summary of Results for Laypersons

The Soft Gel Specialist

Highlighting in the WHO European Region: Summary. No. 21(February 2012)

The EHRA White Book 2010

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

Development of Palliative Care services in different countries

Prevention of Oral Cancer Special Interest Working Group

STAT/SOC/CSSS 221 Statistical Concepts and Methods for the Social Sciences. Introduction to Mulitple Regression

Epidemiology of Legionnaires Disease in Europe Birgitta de Jong on behalf of ELDSNet ESGLI conference 22 September 2016

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

CALL FOR A EUROPEAN ACTION PLAN FOR MEDICAL IMAGING TO IMPROVE QUALITY OF CARE AND PATIENT SAFETY

EUROPEAN AEROSOL PRODUCTION

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

creating value from design to production

Summary. Primary care data. Week 49/2014. Season

CND UNGASS FOLLOW UP

European Collaboration on Dementia. Luxembourg, 13 December 2006

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

World Health Organization Regional Office for Europe Surveillance of measles and rubella Data as of 15 March 2006

Sponsor Novartis Generic Drug Name. Pimecrolimus. Therapeutic Area of Trial. Atopic dermatitis

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Animal health situation of OIE Member Countries in Europe 1 st semester 2012 (and previous)

Country-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank

Appendix F. The Test-Curriculum Matching Analysis Science TIMSS 2011 INTERNATIONAL RESULTS IN SCIENCE APPENDIX F 479

Partner with the Global Leader in Drug Delivery Systems

The Economics of Tobacco Control and Tobacco Taxation: Challenges & Opportunities for a Tobacco Free Turkey

European Association of Dental Public Health Prevention of Oral Cancer

- Network for Excellence in Health Innovation

Transcription:

2014

02 about us Cyndea Pharma is an independent Spanish laboratory specialized in the development and manufacturing of generic formulations all of which is done in the latest state-of-the-art high containment facilities.

03 hormonal contraception endometriosis hormone replacement therapy infertility The main focus of the Company is the manufacturing and development of highly active generic medicines such as hormonal products related to the field of women s health. hormone-dependent cancer treatments Certifications: GMP granted by European Health Authorities I ANVISA I Next steps: FDA

04 milestone Cyndea Pharma

pharmaceutical development services 05 Cyndea Pharma offers a fully integrated approach to the development of highly active molecules in pharmaceutical solid dosage forms. API highly active bulk drug substance Analytical Development Pre-formulation Formulation development Scale-up & Validation Trial Batches, Clinical trials & Test manufacturing Stability, Dossier compilation & Registration Commercial Manufacturing

pharmaceutical development services R&D Personnel: Employees: 60% University Graduates R&D Laboratory capabilities: Equipped with Chromatography Techniques (HPLC, GC) and Conventional Techniques (PSD, DSC, UV, IR, In vitro dissolution...). Stability chambers. High containment isolator for the handling potent drugs. Development and validation of analytical methods. Extensive ICH compliance stability studies. 06 UPLC technologies.

07

pharmaceutical development services Formulation services: Solid dosage forms. Soft Gelatine Capsules. Pilot plant for highly potent molecules. Specific experience in formulating highly potent molecules. 08

Products Products ectd EU Dossiers ectd EU Dossiers Sexual hormones Sexual hormones Prednisone 10 mg products Prednisone 30 mg ANDA US Dossiers Sexual hormones Drospirenone 3 mg + EE 0,03 mg Drospirenone 3 mg + EE 0,03 mg Drospirenone 3 mg + EE 0,03 mg Drospirenone 3 mg + EE 0,02 mg Drospirenone 3 mg + EE 0,02 mg Drospirenone 3 mg + EE 0,02 mg Desogestrel 75 μg Desogestrel 0,150mg + EE 0,02mg + EE0,01mg Desogestrel 75 μg Dienogest 2 mg + EE 0,03 mg Desogestrel 0,150 mg + EE 0,03 mg Dienogest 2 mg + EE 0,03 mg Chlormadinone 2 mg + EE 0,03 mg Levonogestrel 0,1 mg + EE 0,02 mg Chlormadinone 2 mg + EE 0,03 mg Desogestrel 0,150 mg + EE 0,02 mg Norgestimate 0,25 mg + EE 0,35 mg Desogestrel 0,150 mg + EE 0,02 mg Desogestrel 0,150 mg + EE 0,03 mg Desogestrel 0,150 mg + EE 0,03 mg Levonogestrel 0,1 mg + EE 0,02 mg Levonogestrel 0,1 mg + EE 0,02 mg Norgestimate0,25 0,25mg mg++ee EE0,035 0,35 mg Norgestimate mg Norgestimate 0,25 mg + EE 0,35 mg Hormonal products Hormonal products Prednisone 2,5 mg Prednisone 2,5 mg Prednisone 5 mg Prednisone 5 mg Prednisone 10 mg Prednisone 10 mg Prednisone 30 mg Prednisone 30 mg ANDA US Dossiers ANDA US Dossiers Sexual hormones Sexual hormones Drospirenone 3 mg + EE 0,03 mg Cyndea pharma Cyndea pharma 09

CONTRACT MANUFACTURING SERVICES Cyndea Pharma

Cyndea offers contract manufacturing services for highly active molecules in solid dosage forms. Cyndea can meet your outsourcing needs for both potent & conventional solid dose drugs. Cyndea offers segregated manufacturing premises for highly active molecules, with a state-of-theart GMP facility designed to comply with the most demanding environmental and safety regulations. THE PLANT Two segregated manufacturing areas for oral tablets and one for Soft-Gel Line 1: High potency pharmaceuticals (hormones). Dedicated line. Line 2: Slightly potent molecules (Corticosteroids and others). Line 3: Soft gelatine capsules (hormones) Line 4 (2016): soft gelatine capsule (non hormonal) Packaging areas. 2 blister lines 1 bottle line 2015: multiphasic blister line. Warehouse. Pilot Plant. QC Laboratories. R&D Laboratories. FDA: expecting PAI Q4 2014 ANVISA approved

12 layout Cyndea Pharma

DESCRIPTION M2 Administrative area 545 13 Laboratories 545 Production area & tetsing plant 1.860 Maintenance building 420 Technical area (HVAC) 400 Warehouse 1.060 Dispensing/Sampling 160 Total constructed area 7.000 Total site area 30.000

14 contract manufacturing services Personnel: 95 (60% highly-qualified) Production capacity: Line1: Hormones line. Line2: Corticosteroids & others line. Line3: Soft gelatine capsules line. Cyndea Pharma

Cyndea Pharma turnovers 15

16 location we re in46countries Portugal Belgium Albania Kosovo Macedonia Germany Bulgaria Cyprus Czech Republic Slovakia Algeria Finland Greece Israel Guatemala Costa Rica Cuba Uruguay Montenegro Netherlands Hungary Switzerland Serbia Ukraine UK Morocco Tunisia Romania Moldova France New Zeland Malta France Syria Belarus Spain Russia Kazakhstan Mexico Italy Canada South Africa Denmark China Brazil United Arab Emirates

Cyndea Pharma, S.L. Polígono Industrial Emiliano Revilla Sanz Avda. de Ágreda, 31. 42110 Ólvega (Soria). Spain Phone: +34 976 645 474 Fax: +34 976 196 316 location 17 2h 15 min Madrid 1 h Airports

18 location thanks for your attention

19

www.cyndeapharma.com cyndeapharma@cyndeapharma.com MADRID OFFICE: +34 912 85 5655 FACTORY: +34 976 645 474